Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multi-centre, single-arm phase 2 trial (vol 20, pg 1702, 2019)

被引：0
|
作者：
Ceresoli, G. L.
Aerts, J. G.
Dziadziuszko, R.
机构：
来源：
LANCET ONCOLOGY | 2020年 / 21卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E70 / E70
页数：1
相关论文
共 17 条
  • [1] Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial
    Ceresoli, Giovanni L.
    Aerts, Joachim G.
    Dziadziuszko, Rafal
    Ramlau, Rodryg
    Cedres, Susana
    van Meerbeeck, Jan P.
    Mencoboni, Manlio
    Planchard, David
    Chella, Antonio
    Crino, Lucio
    Krzakowski, Maciej
    Russel, Jorn
    Maconi, Antonio
    Gianoncelli, Letizia
    Grosso, Federica
    LANCET ONCOLOGY, 2019, 20 (12): : 1702 - 1709
  • [2] A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol
    Fujimoto, Nobukazu
    Aoe, Keisuke
    Kozuki, Toshiyuki
    Oze, Isao
    Kato, Katsuya
    Kishimoto, Takumi
    Hotta, Katsuyuki
    CLINICAL LUNG CANCER, 2018, 19 (05) : E705 - E707
  • [3] A phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma: JME-001
    Fujimoto, N.
    Kozuki, T.
    Aoe, K.
    Miyamoto, Y.
    Wada, S.
    Harada, D.
    Yoshida, M.
    Sakurai, J.
    Hotta, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S1077 - S1077
  • [4] JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
    Miyamoto, Yosuke
    Kozuki, Toshiyuki
    Aoe, Keisuke
    Wada, Sae
    Harada, Daijiro
    Yoshida, Michihiro
    Sakurai, Jun
    Hotta, Katsuyuki
    Fujimoto, Nobukazu
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (10)
  • [5] Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in
    Nowak, Anna K.
    Lesterhuis, W. Joost
    Kok, Peey-Sei
    Brown, Chris
    Hughes, Brett G. M.
    Karikios, Deme J.
    John, Thomas
    Kao, Steven C-H
    Leslie, Connull
    Cook, Alistair M.
    Pavlakis, Nick
    Briscoe, Karen
    O'Byrne, Kenneth J.
    Karapetis, Christos S.
    Lam, Wei-Sen
    Langford, Ailsa
    Yip, Sonia
    Stockler, Martin R.
    LANCET ONCOLOGY, 2020, 21 (09): : 1213 - 1223
  • [6] Phase I trial of tivantinib in combination with carboplatin and pemetrexed as first-line treatment in patients with advanced nonsquamous non small cell lung cancer or malignant pleural mesothelioma.
    Zucali, Paolo Andrea
    Simonelli, Matteo
    De Vincenzo, Fabio
    Fatuzzo, Giuseppe
    Bertossi, Monica
    Perrino, Matteo
    Miggiano, Chiara
    Giordano, Laura
    Bonifacio, Cristiana
    Sposta, Federica Mrakic
    Santoro, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)
    Metaxas, Y.
    Fruh, M.
    Eboulet, E. I.
    Grosso, F.
    Pless, M.
    Zucali, P. A.
    Ceresoli, G. L.
    Mark, M.
    Schneider, M.
    Maconi, A.
    Perrino, M.
    Biaggi-Rudolf, C.
    Froesch, P.
    Schmid, S.
    Waibel, C.
    Appenzeller, C.
    Rauch, D.
    von Moos, R.
    ANNALS OF ONCOLOGY, 2020, 31 (04) : 495 - 500
  • [8] PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)-A PrECOG LLC study.
    Forde, Patrick M.
    Sun, Zhuoxin
    Anagnostou, Valsamo
    Kindler, Hedy L.
    Purcell, William T.
    Goulart, Bernardo H. L.
    Dudek, Arkadiusz Z.
    Borghaei, Hossein
    Brahmer, Julie R.
    Ramalingam, Suresh S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial (vol 389, pg 67, 2017)
    Balar, A., V
    Galsky, M. D.
    Rosenberg, J. E.
    LANCET, 2017, 390 (10097): : 848 - 848
  • [10] SUCCINCT: An Open-label, Single-arm, Non-randomised, Phase 2 Trial of Gemcitabine and Cisplatin Chemotherapy in Combination with Sunitinib as First-line Treatment for Patients with Advanced Urothelial Carcinoma
    Geldart, Thomas
    Chester, John
    Casbard, Angela
    Crabb, Simon
    Elliott, Tony
    Protheroe, Andrew
    Huddart, Robert A.
    Mead, Graham
    Barber, Jim
    Jones, Robert J.
    Smith, Joanna
    Cowles, Robert
    Evans, Jessica
    Griffiths, Gareth
    EUROPEAN UROLOGY, 2015, 67 (04) : 599 - 602
12